Upadacitinib News
Upadacitinib currently has 2 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Upadacitinib with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more...
- Evidence level: L5
- Predicted indications (20):
- rheumatoid arthritis (99.7%)
- colobomatous microphthalmia-rhizomelic dysplasia syndrome (99.6%)
- brachydactyly-syndactyly syndrome (99.6%)
- indolent plasma cell myeloma (94.4%)
- amyotrohpic lateral sclerosis type 22 (93.2%)
- heparin cofactor 2 deficiency (92.8%)
- amyotrophic lateral sclerosis, susceptibility to (92.8%)
- plasma cell myeloma (92.6%)
- Mills syndrome (91.9%)
- amyotrophic lateral sclerosis (91.9%)
- axial spondylometaphyseal dysplasia (91.3%)
- factor 5 excess with spontaneous thrombosis (90.5%)
- antithrombin deficiency type 2 (90.3%)
- bilateral parasagittal parieto-occipital polymicrogyria (89.6%)
- monomelic amyotrophy (88.9%)
- trichomegaly-retina pigmentary degeneration-dwarfism syndrome (88.5%)
- lower motor neuron syndrome with late-adult onset (87.2%)
- lethal arthrogryposis-anterior horn cell disease syndrome (86.7%)
- autosomal dominant mitochondrial myopathy with exercise intolerance (86.4%)
- myeloid leukemia (84.9%)
Related News (2)
A surprisingly simple way to relieve knee arthritis pain without pills or surgery - Science Daily
2026-10-11 arthritis
Source: Science Daily
Knee pain and crunching: 3 exercises to ease osteoarthritis of the kneecap - South China Morning Post
2026-10-09 arthritis
Source: South China Morning Post
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.